Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297821449> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4297821449 endingPage "S1097" @default.
- W4297821449 startingPage "S1097" @default.
- W4297821449 abstract "The majority of uncommon epidermal growth factor receptor mutations (EGFRm) showed decreased sensitivity to EGFR- tyrosine kinase inhibitor (TKI) when compared to common EGFRm. Osimertinib as first-line therapy showed promising efficacy in non-small cell lung cancer (NSCLC) patients with EGFR G719X/L861Q/S768I mutations. While the addition of chemotherapy to gefitinib markedly improved the progression-free survival and overall survival of sensitive EGFRm NSCLC, with an acceptable toxicity profile, osimertinib in combination with chemotherapy may extend the clinical benefits in uncommon EGFRm NSCLC. This study will evaluate the efficacy and safety of osimertinib plus platinum and pemetrexed chemotherapy in untreated locally advanced/metastatic NSCLC patients with uncommon EGFRm. This is a phase II, open-label, single arm, multicenter and exploratory study. Stage IIIB-IVB treatment-naïve non-squamous NSCLC patients with at least 1 of the 4 uncommon EGFRm (G719X/L861Q/S768I/de novo T790M) but without ex19del/L858R will be enrolled. Those with asymptomatic and stable central nervous system (CNS) metastases are eligible. The subjects (N = 35) will receive 80mg osimertinib QD p.o. plus standard chemotherapy composed of cisplatin or carboplatin and pemetrexed i.v. on Day 1 of a 21-day cycle (every 3 weeks) for 4 to 6 cycles, followed by osimertinib 80 mg QD p.o. plus pemetrexed maintenance i.v. every 3 weeks until RECIST 1.1-defined radiological progression or intolerance as judged by the investigator. The primary outcome endpoint is objective response rate (ORR, per RECIST 1.1 using investigator assessments). Secondary endpoints include progression-free survival (PFS) and overall survival (OS), duration of response (DoR), disease control rate (DCR), depth of response, time to treatment failure or death (TTF) and time to first subsequent therapy or death (TFST) (all assessed by investigator per RECIST 1.1). Resistance profile in plasma circulating tumor deoxyribonucleic acid (ctDNA) will be evaluated as exploratory endpoint. NCT05215951. AstraZeneca. AstraZeneca." @default.
- W4297821449 created "2022-10-01" @default.
- W4297821449 creator A5023519850 @default.
- W4297821449 creator A5055881823 @default.
- W4297821449 creator A5063866219 @default.
- W4297821449 creator A5067979680 @default.
- W4297821449 creator A5090196339 @default.
- W4297821449 date "2022-09-01" @default.
- W4297821449 modified "2023-09-27" @default.
- W4297821449 title "1201TiP MINOVA: A phase II, open-label, single arm, multicenter, exploratory study with osimertinib plus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations" @default.
- W4297821449 doi "https://doi.org/10.1016/j.annonc.2022.07.1877" @default.
- W4297821449 hasPublicationYear "2022" @default.
- W4297821449 type Work @default.
- W4297821449 citedByCount "0" @default.
- W4297821449 crossrefType "journal-article" @default.
- W4297821449 hasAuthorship W4297821449A5023519850 @default.
- W4297821449 hasAuthorship W4297821449A5055881823 @default.
- W4297821449 hasAuthorship W4297821449A5063866219 @default.
- W4297821449 hasAuthorship W4297821449A5067979680 @default.
- W4297821449 hasAuthorship W4297821449A5090196339 @default.
- W4297821449 hasBestOaLocation W42978214491 @default.
- W4297821449 hasConcept C121608353 @default.
- W4297821449 hasConcept C126322002 @default.
- W4297821449 hasConcept C143998085 @default.
- W4297821449 hasConcept C203092338 @default.
- W4297821449 hasConcept C2776232967 @default.
- W4297821449 hasConcept C2776256026 @default.
- W4297821449 hasConcept C2776694085 @default.
- W4297821449 hasConcept C2777240266 @default.
- W4297821449 hasConcept C2777626846 @default.
- W4297821449 hasConcept C2777930144 @default.
- W4297821449 hasConcept C2778087573 @default.
- W4297821449 hasConcept C2778239845 @default.
- W4297821449 hasConcept C2779177807 @default.
- W4297821449 hasConcept C2779422266 @default.
- W4297821449 hasConcept C2779438470 @default.
- W4297821449 hasConcept C2779750558 @default.
- W4297821449 hasConcept C2779984678 @default.
- W4297821449 hasConcept C2780580887 @default.
- W4297821449 hasConcept C2781451048 @default.
- W4297821449 hasConcept C31760486 @default.
- W4297821449 hasConcept C535046627 @default.
- W4297821449 hasConcept C71924100 @default.
- W4297821449 hasConcept C81729549 @default.
- W4297821449 hasConceptScore W4297821449C121608353 @default.
- W4297821449 hasConceptScore W4297821449C126322002 @default.
- W4297821449 hasConceptScore W4297821449C143998085 @default.
- W4297821449 hasConceptScore W4297821449C203092338 @default.
- W4297821449 hasConceptScore W4297821449C2776232967 @default.
- W4297821449 hasConceptScore W4297821449C2776256026 @default.
- W4297821449 hasConceptScore W4297821449C2776694085 @default.
- W4297821449 hasConceptScore W4297821449C2777240266 @default.
- W4297821449 hasConceptScore W4297821449C2777626846 @default.
- W4297821449 hasConceptScore W4297821449C2777930144 @default.
- W4297821449 hasConceptScore W4297821449C2778087573 @default.
- W4297821449 hasConceptScore W4297821449C2778239845 @default.
- W4297821449 hasConceptScore W4297821449C2779177807 @default.
- W4297821449 hasConceptScore W4297821449C2779422266 @default.
- W4297821449 hasConceptScore W4297821449C2779438470 @default.
- W4297821449 hasConceptScore W4297821449C2779750558 @default.
- W4297821449 hasConceptScore W4297821449C2779984678 @default.
- W4297821449 hasConceptScore W4297821449C2780580887 @default.
- W4297821449 hasConceptScore W4297821449C2781451048 @default.
- W4297821449 hasConceptScore W4297821449C31760486 @default.
- W4297821449 hasConceptScore W4297821449C535046627 @default.
- W4297821449 hasConceptScore W4297821449C71924100 @default.
- W4297821449 hasConceptScore W4297821449C81729549 @default.
- W4297821449 hasLocation W42978214491 @default.
- W4297821449 hasOpenAccess W4297821449 @default.
- W4297821449 hasPrimaryLocation W42978214491 @default.
- W4297821449 hasRelatedWork W2112474794 @default.
- W4297821449 hasRelatedWork W2503069423 @default.
- W4297821449 hasRelatedWork W2568141701 @default.
- W4297821449 hasRelatedWork W2569956255 @default.
- W4297821449 hasRelatedWork W2571285332 @default.
- W4297821449 hasRelatedWork W2613038040 @default.
- W4297821449 hasRelatedWork W3093099883 @default.
- W4297821449 hasRelatedWork W3195265131 @default.
- W4297821449 hasRelatedWork W4281670385 @default.
- W4297821449 hasRelatedWork W4297821449 @default.
- W4297821449 hasVolume "33" @default.
- W4297821449 isParatext "false" @default.
- W4297821449 isRetracted "false" @default.
- W4297821449 workType "article" @default.